Cipla, Stempeutics Launch Stem Cell Therapy for Knee Osteoarthritis

Key facts

• Cipla Limited, in partnership with Stempeutics Research, launched Ciplostem, an innovative allogeneic mesenchymal stromal cell (MSC) therapy for knee osteoarthritis (knee OA).
• The treatment is approved by the Drug Controller General of India (DCGI).
• The treatment offers to slow disease progression and promote cartilage maintenance for patients with Grade II and III knee OA.
• Ciplostem is an allogeneic mesenchymal stromal cell (MSC) therapy, which implies that this is not customised or patient-specific stem cell therapy, and can be administered off the shelf.
• Ciplostem is administered as a single-dose, intra-articular injection containing 25 million cultured adult human bone marrow-derived mesenchymal stem cells (BM-MSCs), co-administered with hyaluronic acid.
• The therapy works at a cellular level to reduce inflammation and pain, enhance joint function, and help preserve cartilage quality.
• The launch addresses a critical unmet need in India, where knee OA affects over 48.4 million people.